Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Sclerema Neonatorum : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Hutchinson-Gilford Progeria

Scleredema

Subcutaneous Fat Necrosis of the Newborn




Patient Education
Click here for patient education.



Author: Amy J Theos, MD, Director of Pediatric Dermatology, Assistant Professor, Department of Dermatology, University of Alabama at Birmingham

Amy J Theos is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, and Society for Pediatric Dermatology

Coauthor(s): Craig A Elmets, MD, Director of Dermatology, Departments of Dermatology, Pathology, and Environmental Health Sciences; Professor, The Kirklin Clinic, University of Alabama at Birmingham

Editors: Daniel Mark Siegel, MD, MS, Director, Procedural Dermatology Fellowship Program, Clinical Professor of Dermatology, Department of Dermatology, State University of New York Downstate; Richard P Vinson, MD, Assistant Clinical Professor, Department of Dermatology, Texas Tech University School of Medicine; Consulting Staff, Mountain View Dermatology, PA; Van Perry, MD, Assistant Professor, Department of Medicine, Division of Dermatology, University of Texas Health Science Center; Joel M Gelfand, MD, MSCE, Medical Director, Clinical Studies Unit, Assistant Professor, Department of Dermatology, Associate Scholar, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania; Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center

Author and Editor Disclosure

Synonyms and related keywords: SN, skinbound disease, skin-bound disease, subcutaneous fat disorder, neonatal subcutaneous fat disorder, neonatal subcutaneous fat disease

Background

The classic description of sclerema neonatorum (SN) is credited to Underwood, who described it in 1784 and appropriately termed it "skinbound disease." In 1817, Alibert introduced the term sclerema, derived from the Greek word skleros, meaning hard. SN is a disorder of the subcutaneous fat in debilitated neonates and is considered best as a sign of a potentially fatal underlying disease process and not a specific disease entity (Warwick, 1963).

Pathophysiology

In an infant, fat has a higher saturated-to-unsaturated fatty acid ratio compared to adult fat and thus, a higher melting point. Prematurity, hypothermia, shock, and metabolic abnormalities have been postulated to further increase this ratio, possibly as a result of enzymatic alteration allowing precipitation of fatty acid crystals within the lipocytes. This condition has been suggested to result in the dramatic clinical findings in affected skin. X-ray diffraction techniques have confirmed that infants with SN have an increase in saturated fats and that the crystals within the fat cells are composed of triglycerides (Kellum, 1968).

Frequency

United States

The exact incidence of SN is unknown. All studies describe SN as extremely rare. The number of reported cases in recent years has declined, probably as a result of better neonatal care.

Mortality/Morbidity

Because SN invariably is associated with serious underlying disease, the mortality rate is high. In different series, the reported mortality rates range from 67-88%, with death occurring hours to days after onset. If the underlying disease is treated successfully, the skin softens and returns to normal.

Race

No racial predilection has been reported.

Sex

SN shows a slight male predominance, with an estimated male-to-female ratio of 1.5:1.

Age

SN is a disease confined to the newborn period. SN can present at birth, but onset within the first week of life is more common. The oldest reported infant presented with Pseudomonas septicemia at age 106 days.



History

One half of affected infants are premature, and the others are full term but have a serious underlying illness. They are often of low birth weight (<2500 g) and have cyanosis and low Apgar scores (Milunsky, 1966). In one series, 75% of the mothers were healthy, while 25% had preeclampsia, placenta previa, or infection. Labor is usually normal, and delivery is spontaneous and nontraumatic.

Physical

Physical findings appear suddenly, first on the thighs and buttocks and then, spreading rapidly, often affecting all parts of the body except the palms, soles, and genitalia. The involved skin is pale, waxy, and firm to palpation. The skin cannot be pitted or pinched up because it is bound to the underlying tissues. The affected infant often displays flexion contractures at the elbows, knees, and hips; temperature instability; restricted respiration; difficulty in feeding; and decreased spontaneous movement.

Causes

Associated underlying conditions include pneumonia, septicemia, hypothermia, metabolic acidosis, respiratory distress syndrome, congenital heart defects, gastroenteritis, and intestinal obstruction.



Hutchinson-Gilford Progeria
Scleredema
Subcutaneous Fat Necrosis of the Newborn

Other Problems to be Considered

Congenital lymphedema (Milroy disease)
Neonatal cold injury
Restrictive dermopathy
Scleroderma



Lab Studies

  • Laboratory abnormalities correlate with the underlying disease process. Hypoglycemia, metabolic acidosis, respiratory alkalosis, hyperkalemia, hypocalcemia, and elevated blood urea are common, albeit nonspecific, findings. A complete sepsis workup should be initiated in all infants.

Histologic Findings

Histologic findings are subtle. The most consistent findings are edema, a thickening of the subcutaneous fibrous septa, and a radial array of fine needlelike clefts in the fat cells. The fat cells often are enlarged. In contrast to subcutaneous fat necrosis of the newborn, no necrosis of the fat or granulomatous inflammation exists.



Medical Care

Recognition and the prompt institution of therapy specific for the underlying disease are mandatory. Careful monitoring, correction of electrolyte abnormalities, respiratory support, correction of hypovolemia, and control of hypothermia are important.

  • Antibiotics: Some authors advocate the prompt institution of prophylactic broad-spectrum antibiotic therapy for possible associated sepsis.
  • Systemic steroids: The value of systemic steroids is controversial. No controlled studies have demonstrated improved survival with the use of systemic steroids, although they are often used.
  • Exchange transfusions: A randomized controlled trial demonstrated a significant survival benefit in septic neonates with SN who were treated with exchange transfusion (Sadana, 1997).

Consultations

  • Infants with SN are best cared for in a neonatal intensive care unit by an intensivist.
  • Depending on the underlying illness (e.g., sepsis), consultation to the appropriate specialists should be made.



Medical therapy of the skin is not beneficial; successful treatment of the underlying disorder improves the skin.



Complications

  • Unless the underlying disease is identified and treated, the course is one of rapid deterioration in the general health of the infant and, ultimately, death.

Prognosis

  • If the infant survives and the underlying condition is treated successfully, no long-term adverse effects are noted. The condition of the skin returns to normal.



Medical/Legal Pitfalls

  • SN is a sign of underlying disease; therefore, failure to identify SN and diagnose the underlying condition may put patients at risk for the complications and mortality of that disease.



  • Battin M, Harding J, Gunn A. Sclerema neonatorum following hypothermia. J Pediatr Child Health. 2002;38:533-4. [Medline].
  • Bwibo NO, Anderson BT. Sclerema neonatorum (a study of 16 cases in the special care unit, Mulago Hospital, Kampala). East Afr Med J. Jan 1970;47(1):50-5. [Medline].
  • Fretzin DF, Arias AM. Sclerema neonatorum and subcutaneous fat necrosis of the newborn. Pediatr Dermatol. Aug 1987;4(2):112-22. [Medline].
  • Hughes W, Hammond M. Sclerema neonatorum. J Pediatr. 1948;32:676-92.
  • Kellum RE, Ray TL, Brown GR. Sclerema neonatorum. Report of a case and analysis of subcutaneous and epidermal-dermal lipids by chromatographic methods. Arch Dermatol. Apr 1968;97(4):372-80. [Medline].
  • Milunsky A, Levin SE. Sclerema neonatorum: a clinical study of 79 cases. S Afr Med J. Jul 2 1966;40(27):638-41. [Medline].
  • Sadana S, Mathur NB, Thakur A. Exchange transfusion in septic neonates with sclerema: effect on immunoglobulin and complement levels. Indian Pediatr. Jan 1997;34(1):20-5. [Medline].
  • Warwick WJ, Ruttenberg HD, Quie PG. Sclerema neonatorum--a sign, not a disease. JAMA. Jun 1 1963;184:680-3. [Medline].

Sclerema Neonatorum excerpt

Article Last Updated: Oct 2, 2006